{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-191945","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2023-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.386717+00:00","generated_at":"2026-06-13T04:03:23.084474+00:00","sec_items":["1.02","5.07","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MEI Pharma terminates merger with Infinity after stockholder vote fails","bullets":["Stockholders voted against merger: 47.86% for, 51.44% against; turnout 59.70% of outstanding shares.","MEI terminated the Merger Agreement with Infinity on July 23, 2023, effective immediately.","Company will continue development of Voruciclib and ME-344; clinical data expected around year-end.","CEO David M. Urso stated focus on capturing stockholder value from pipeline programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-191945","json":"https://secwatch.observer/filing/0001193125-23-191945.json","markdown":"https://secwatch.observer/filing/0001193125-23-191945.md","text":"https://secwatch.observer/filing/0001193125-23-191945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523191945/0001193125-23-191945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523191945/d442693d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T04:03:23.084474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b4a672593a69b9cd015ecd8f56f8a1ec6ae74334","claim":"Lite Strategy, Inc. shareholders rejected Proposal to consider and vote upon the proposal to approve, for purposes of Nasdaq Listing Rule 5635(a), of the issuance of shares of MEI Common Stock to stockholders of Infinity pursuant to the terms of the Merger Agreement at the 2023-07-23 meeting.","evidence_excerpt":"Proposal No. 1 – Proposal to consider and vote upon the proposal to approve, for purposes of Nasdaq Listing Rule 5635(a), of the issuance of shares of MEI Common Stock, $0.00000002 par value per share, to stockholders of Infinity pursuant to the terms of the Merger Agreement, was as follows: For Against Abstain 1,903,448 2,046,283 27,986","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523191945/0001193125-23-191945-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"merger approval"},{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2023-07-23"}],"fact_type":"shareholder_vote"},{"claim_id":"bbf27a9c5a5a0278ca3702f87e5b53b6c7f72a93","claim":"Lite Strategy, Inc. shareholders rejected Proposal to consider and vote upon the proposal to approve the adjournment of the Special Meeting, from time to time, if necessary or appropriate, including to solicit additional proxies in the event that there are insufficient votes at the time of the Special Meeting or any adjournment or postponem at the 2023-07-23 meeting.","evidence_excerpt":"Proposal No. 2 – Proposal to consider and vote upon the proposal to approve the adjournment of the Special Meeting, from time to time, if necessary or appropriate, including to solicit additional proxies in the event that there are insufficient votes at the time of the Special Meeting or any adjournment or postponement thereof to approve Proposal No. 1, was as follows: For Against Abstain 1,926,950 2,014,469 36,298","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523191945/0001193125-23-191945-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2023-07-23"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}